High-throughput screening strategy identifies allosteric, covalent human D-amino acid oxidase inhibitor

Journal of Biomolecular Screening

Volumn 20, Issue 10, 2015, Pages 1218-1231

  Terry Lorenzo, Ryan T ^a   Masuda, Keiki ^a   Sugao, Kohtaroh ^a   Fang, Q Kevin ^a   Orsini, Michael A ^a   Sacchi, Silvia ^b   Pollegioni, Loredano ^b  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

covalent inhibitors; D serine; neuropathic pain; schizophrenia

Indexed keywords

CYSTEINE; DEXTRO AMINO ACID OXIDASE; GLUTATHIONE; HUMAN D AMINO ACID OXIDASE INHIBITOR; OXIDOREDUCTASE INHIBITOR; TARTARIC ACID; UNCLASSIFIED DRUG; CARRIER PROTEIN; DAOA PROTEIN, HUMAN;

ALLOSTERISM; ARTICLE; BINDING SITE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DILUTION; ENZYMATIC ASSAY; ENZYME ACTIVITY; HIGH THROUGHPUT SCREENING; HILL COEFFICIENT; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; STEADY STATE; STOICHIOMETRY; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEURALGIA; SCHIZOPHRENIA;

ALLOSTERIC SITE; CARRIER PROTEINS; D-AMINO-ACID OXIDASE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; NEURALGIA; SCHIZOPHRENIA;

EID: 84948407941     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057115600413     Document Type: Article

References (35)

1. Sacchi S., Caldinelli L., Cappelletti P., et al. Structure-Function Relationships in Human D-Amino Acid Oxidase. Amino Acids 2012, 43, 1833-1850.
2. Papouin T., Ladepeche L., Ruel J., et al. Synaptic and Extrasynaptic NMDA Receptors Are Gated by Different Endogenous Coagonists. Cell 2012, 150, 633-646.
3. Zhou Q., Sheng M., NMDA Receptors in Nervous System Diseases. Neuropharmacology 2013, 74, 69-75.
4. Hopkins S. C., Campbell U. C., Heffernan M. L., et al. Effects of D-Amino Acid Oxidase Inhibition on Memory Performance and Long-Term Potentiation. Pharma. Res. Per. 2013, 1, e00007, 1-9.
5. Chumakov I., Blumenfeld M., Guerassimenko O., et al. Genetic and Physiological Data Implicating the New Human Gene G72 and the Gene for D-Amino Acid Oxidase in Schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 13675-13680.
6. Drews E., Otte D. M., Zimmer A., Involvement of the Primate Specific Gene G72 in Schizophrenia: From Genetic Studies to Pathomechanisms. Neurosci. Biobehav. Rev. 2013, 37 (Pt. 1), 2410-2417.
7. Sacchi S., Bernasconi M., Martineau M., et al. pLG72 Modulates Intracellular D-Serine Levels through Its Interaction with D-Amino Acid Oxidase: Effect on Schizophrenia Susceptibility. J. Biol. Chem. 2008, 283, 22244-22256.
8. Sacchi S., Cappelletti P., Giovannardi S., et al. Evidence for the Interaction of D-Amino Acid Oxidase with pLG72 in a Glial Cell Line. Mol. Cell. Neurosci. 2011, 48, 20-28.
9. Kvajo M., Dhilla A., Swor D. E., et al. Evidence Implicating the Candidate Schizophrenia/Bipolar Disorder Susceptibility Gene G72 in Mitochondrial Function. Mol. Psychiatry 2008, 13, 685-696.
10. Benzel I., Kew J. N., Viknaraja R., et al. Investigation of G72 (DAOA) Expression in the Human Brain. BMC Psychiatry 2008, 8, 94.
11. Otte D. M., Sommersberg B., Kudin A., et al. N-Acetyl Cysteine Treatment Rescues Cognitive Deficits Induced by Mitochondrial Dysfunction in G72/G30 Transgenic Mice. Neuropsychopharmacology 2011, 36, 2233-2243.
12. Sparey T., Abeywickrema P., Almond S., et al. The Discovery of Fused Pyrrole Carboxylic Acids as Novel, Potent D-Amino Acid Oxidase (DAO) Inhibitors. Bioorg. Med. Chem. Lett. 2008, 18, 3386-3391.
13. Bhakuni B. S., Balkrishna S. J., Kumar A., et al. An Efficient Copper Mediated Synthetic Methodology for Benzo[d]isothiazol-3(2H)-ones and Related Sulfur-Nitrogen Heterocycles. Tetrahedron Lett. 2012, 53, 1354-1357.
14. Terry-Lorenzo R. T., Chun L. E., Brown S. P., et al. Novel Human D-Amino Acid Oxidase Inhibitors Stabilize an Active-Site Lid-Open Conformation. Biosci. Rep. 2014, 34, e00133.
15. Fang K. Q., Hopkins S., Jones S., Benzo[d]isoxazol-3-ol DAAO Inhibitors. Patent WO2005066143A2. 20, 2005.
16. Shi G., The First General Synthesis of N-Substituted 1,2-Benzisoxazolin-3-ones. Tetrahedron Let. 2000, 41, 2295-2298.
17. Molla G., Sacchi S., Bernasconi M., et al. Characterization of Human D-Amino Acid Oxidase. FEBS Lett. 2006, 580, 2358-2364.
18. Molla G., Bernasconi M., Sacchi S., et al. Expression in Escherichia coli and In Vitro Refolding of the Human Protein pLG72. Protein Expression Purif. 2006, 46, 150-155.
19. Frattini L. F., Piubelli L., Sacchi S., et al. Is Rat an Appropriate Animal Model to Study the Involvement of D-Serine Catabolism in Schizophrenia? Insights from Characterization of D-Amino Acid Oxidase. FEBS J. 2011, 278, 4362-4373.
20. Negri A., Tedeschi G., Ceciliani F., et al. Purification of Beef Kidney D-Aspartate Oxidase Overexpressed in Escherichia coli and Characterization of Its Redox Potentials and Oxidative Activity towards Agonists and Antagonists of Excitatory Amino Acid Receptors. Biochim. Biophys. Acta 1999, 1431, 212-222.
21. Simonic T., Duga S., Negri A., et al. cDNA Cloning and Expression of the Flavoprotein D-Aspartate Oxidase from Bovine Kidney Cortex. Biochem. J. 1997, 322 (Pt. 3), 729-735.
22. Caldinelli L., Molla G., Bracci L., et al. Effect of Ligand Binding on Human D-Amino Acid Oxidase: Implications for the Development of New Drugs for Schizophrenia Treatment. Protein Sci. 2010, 19, 1500-1512.
23. Chang S. L., Hsieh C. H., Chen Y. J., et al. The C-Terminal Region of G72 Increases D-Amino Acid Oxidase Activity. Int. J. Mol. Sci. 2014, 15, 29-43.
24. Zhang J. H., Chung T. D., Oldenburg K. R., A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen. 1999, 4, 67-73.
25. Lu J., Vlamis-Gardikas A., Kandasamy K., et al. Inhibition of Bacterial Thioredoxin Reductase: An Antibiotic Mechanism Targeting Bacteria Lacking Glutathione. FASEB J. 2013, 27, 1394-1403.
26. Lu J., Vodnala S. K., Gustavsson A. L., et al. Ebsulfur Is a Benzisothiazolone Cytocidal Inhibitor Targeting the Trypanothione Reductase of. Trypanosoma brucei. J. Biol. Chem. 2013, 288, 27456-27468.
27. Ferraris D., Duvall B., Ko Y. S., et al. Synthesis and Biological Evaluation of D-Amino Acid Oxidase Inhibitors. J. Med. Chem. 2008, 51, 3357-3359.
28. Collier P. J., Ramsey A., Waigh R. D., et al. Chemical Reactivity of Some Isothiazolone Biocides. J. Appl. Bacteriol. 1990, 69, 578-584.
29. Trevillyan J. M., Chiou X. G., Ballaron S. J., et al. Inhibition of p56(lck) Tyrosine Kinase by Isothiazolones. Arch. Biochem. Biophys. 1999, 364, 19-29.
30. Cappelletti P., Campomenosi P., Pollegioni L., et al. The Degradation (by Distinct Pathways) of Human D-Amino Acid Oxidase and Its Interacting Partner pLG72-Two Key Proteins in D-Serine Catabolism in the Brain. FEBS J. 2014, 281, 708-723.
31. Caldinelli L., Molla G., Sacchi S., et al. Relevance of Weak Flavin Binding in Human D-Amino Acid Oxidase. Protein Sci. 2009, 18, 801-810.
32. Baell J. B., Ferrins L., Falk H., et al. PAINS: Relevance to Tool Compound Discovery and Fragment-Based Screening. Aust. J. Chem. 2013, 66, 1483-1494.
33. Singh N., Halliday A. C., Thomas J. M., et al. A Safe Lithium Mimetic for Bipolar Disorder. Nat. Commun. 2013, 4, 1332.
34. Dahl R., Bravo Y., Sharma V., et al. Potent, Selective, and Orally Available Benzoisothiazolone Phosphomannose Isomerase Inhibitors as Probes for Congenital Disorder of Glycosylation Ia. J. Med. Chem. 2011, 54, 3661-3668.
35. Sharma V., Ichikawa M., He P., et al. Phosphomannose Isomerase Inhibitors Improve N-Glycosylation in Selected Phosphomannomutase-Deficient Fibroblasts. J. Biol. Chem. 2011, 286, 39431-39438.